Treating Depression in Adolescents

Dr. Vitiello is Chief of the Child and Adolescent Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Room 7149, 6001 Executive Blvd, MSC 9633, Bethesda, MD 20892; E-mail: [email protected], and Professor (adjunct) of Psychiatry at the Johns Hopkins University, Baltimore, MD. The opinions and assertions contained in this report are the private views of the author and are not to be construed as official or as reflecting the views of the Department of Health and Human Services or the National Institutes of Health. The author and all staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity. Dr. Vitiello has disclosed that the use of antidepressants other than fluoxetine or escitalopram for the treatment of depression in adolescents as discussed in this article has not been approved by the U.S. Food and Drug Administration and constitutes off-label use.